LBRX
LB Pharmaceuticals Inc (NASDAQ)
Healthcare — Biotechnology
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York.
Strong Buy
1.2 / 5
6 analysts
$31.89
$-0.57 (-1.74%)
Target:
$45.00
(41.1%)
Sign in to add LBRX to a watchlist or set price alerts.
Price History
52-Week Range
Fundamentals
| Market Cap | $914.50M |
| P/E Ratio (TTM) | - |
| Forward P/E | -7.10 |
| EPS (TTM) | $-1.36 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -19.56% |
| Debt/Equity | 0.92 |
| Recommendation | Strong Buy 1.2 |
| Analyst Target | $45.00 |
| Analysts | 6 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 73.3 |
| Beta | - |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $33.47 |
| 52-Week Low | $13.36 |
| 50-Day Avg | $30.04 |
| 200-Day Avg | $22.83 |
| Avg Volume | 262.0K |
| Volume | 217.4K |
Performance Analysis
NEUTRALLBRX presents a mixed picture with both positive and negative indicators.
-
Trading near its 52-week high ($33.47), which may indicate limited upside.
-
RSI at 73.3 indicates overbought conditions — a pullback may be due.
+
Price is above both the 50-day and 200-day moving averages — strong uptrend.
+
Wall Street consensus is "Strong Buy" from 6 analysts.
+
Average analyst target of $45.00 implies 41.1% upside.
Recent News
Loading news...
Last updated: Jul 02, 2026 13:17 UTC
Back to Screener Export Report